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Sorsby's fundus dystrophy {SFD} has been mapped to a genetic interval of 8 cM between loci D225275 and 
D22S278. A total of 15 families, unrelated on the basis of genealogy and expressing the SFD phenotype were 
identified from a large data base of genetic eye disease families originating from diverse parts of the British 
Isles. The identification of the same SerlSICys mutation cosegregating with disease in each family led us to 
consider the hypothesis of a founder effect being present. In all families studied, the same relatively 
infrequent allele (occurring in just 11°/0 of the control group} was associated with disease at marker locus 
D22S280. A highly significant disease-associated haplotype, spanning across 3 cM of the SFD locus, was 
conserved in 11 of the 15 families {68% of all affected chromosomes}; a further extended haplotype spanning 
up to 7 cM, was identified in 5 families {27% of SFD-associated chromosomes} and possibly represents the 
ancestral haplotype. This haplotype analysis has refined the TlhlP3 gene localization to a I- to 3-cM interval 
between marker loci D22S273 and D22S281 and provides strong evidence for a single mutational event being 
responsible for the majority of SFD identified in the British Isles. 
Sorsby's fundus dystrophy (SFD) is a fully pene- 
trant, autosomal dominant  retinal dystrophy 
(Sorsby and Mason 1949), characterized by the 
loss of central vision as a result of macular disease 
by the fourth to fifth decade and peripheral vi- 
sual loss in late life. Histopathological studies 
show accumulation of material internal to the 
basement membrane of the retinal pigment epi- 
thelium, reaching as much as 30 ~LM in thickness. 
Both clinically and histopathological ly SFD 
shares some similarities with age-related macular 
degeneration (ARMD), a major cause of blindness 
in the developed world. The SFD locus was ini- 
tially localized to chromosome 22q13-ter (Weber 
et al. 1994a) and subsequently refined to an 8-cM 
interval between loci D22S275 and D22S278 
(Gregory et al. 1995). Two mutations, Tyr168Cys 
and Ser181Cys, of the gene encoding tissue in- 
hibitor of metalloproteinases-3 (TIMP3), also 
mapping to 22q12.1-q13.2 (Apte et al. 1994), 
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have been shown to segregate with disease in two 
separate North American SFD pedigrees (Weber 
et al. 1994b). Recently, new SFD families with 
mutations in TIMP3 at codon Ser156Cys (Felbor 
et al. 1995) and codon Gly167Cys (Jacobson et al. 
1995) have been described. TIMP3 is present in 
the extracellular matrix of various tissues and the 
presence of a TIMP-like protein recently has been 
reported in the interphotoreceptor matrix (Gallo 
et al. 1994). In SFD the TIMP3 protein may be 
directly or indirectly responsible for the deposi- 
tion of material at the level of Bruch's membrane, 
which may subsequently ead to the manifesta- 
tion of the SFD phenotype. 
Data associating particular alleles of marker 
loci with disease phenotype can be used in the 
refinement of disease gene loci (Kerem et al. 
1989; Bowcock et al. 1994). Such data may also be 
used to construct haplotypes of genomic regions 
inclusive of a disease locus. This has led to the 
identification of founder effects, with the disease- 
causing mutation tracing back to a relatively 
small number of ancestors, in a number of stud- 
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ies (Sirugo et al. 1992; Oudet et al. 1993; Petty et 
al. 1994). In this study we identify the same 
T1MP3 mutation and haplotype data in a rela- 
tively large number of SFD families, suggesting 
that a similar founder effect may be responsible 
for the majority of SFD identified in the British 
Isles. From these data we also infer a more precise 
genetic localization for the TIMP3 gene. 
RESULTS 
By direct sequencing and NsiI digestion the 
Ser181Cys mutation of TIMP3 was identified in 
all 76 affected members from the 15 SFD families 
included in the study. This mutation was seen to 
cosegregate with the disease phenotype across all 
families and was not present in any unaffected 
individuals or spouses (Figure 1). This evidence 
suggested that the Ser181Cys mutation could be 
the result of a founder effect. 
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Figure 1 Cosegregation of SFD with the 
Ser181Cys mutation of TIMP3 in a branch of family 
11. Ns~l digestion of a PCR-amplified product of 240 
bp results in two fragments of 200 and 40 bp in 
affected individuals. The smaller 40-bp fragment is 
not seen in the ethidium bromide-stained 8% non- 
denaturing polyacrylamide gel depicted. All af- 
fected individuals are heterozygous for the mutation 
as both the 240 and 200-bp fragment are observed. 
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Allelic Association Studies 
All families were informative for all marker loci 
tested, and for each marker the disease bearing 
chromosome could be identified. Twenty-two 
different disease haplotypes and 54 control hap- 
lotypes (27 individuals) were compared by Z2 
square and likelihood ratio test (LRT) analysis. 
Significant allelic association with disease was 
observed at marker loci D22S275, D22S273, 
D22S280, and D22S281, covering a 4-cM region 
(Table 1). Significant linkage disequilibrium esti- 
mated by Yules coefficient (5) was observed be- 
tween SFD and all of the above markers loci with 
the highest 6-- 1 being observed with D22S275 
and D22S280. 
Table 1 presents allelic association data for 
normal and SFD chromosomes. The 176-bp allele 
of locus D22S275 was associated with disease in 
9/22 (41%) SFD chromosomes and was not rep- 
resented in the normal control population. This 
association, however, reached significance with 
only the conventional Z 2 analysis. Both statistical 
tests provided significant associations between 
the 198-bp allele of locus D22S273, 2 cM distal to 
D22S275, which was present in 18/22 (81%) SFD 
chromosomes versus 15% normal chromosomes. 
Similarly the 218-bp allele of locus D22S280 and 
the 135-bp allele for locus D22S281, lying 2 and 3 
cM distal to D22S273, respectively, accounted for 
22/22 (100%) and 18/22 (81%) SFD chromo- 
somes and 11% and 20% normal controls, respec- 
tively. Using both statistical tests, these associa- 
tions reached high levels of significance. Neither 
test provided significant associations between 
SFD and alleles of D22S278, a marker lying 4 cM 
distal to D22S281. In the control population, al- 
leles in addition to those published previously 
based on Centre d'Etude du Polymorphisme Hu- 
main (CEPH) family data were identified at loci 
D22S275, D22S273, D22S280, and D22S281. 
Haplotype Association 
The 15 SFD families we studied were presumed 
unrelated even though some families came from 
the same area (Table 2), because they could not 
be linked by genealogy (See Subjects and Materi- 
als). Thus, we used microsatellite-generated hap- 
lotypes to try to establish a common lineage. 
Haplotypes egregating with the disease were 
constructed to identify a possible ancestral hap- 
lotype. Of a possible 43,200 haplotypes that 
could arise from the 5 tested markers, 160 were 
observed in our study population. The distribu- 
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Table 1. Allelic Association for CA(n) Marker Loci on Normal and SFD Chromosomes 
No. SFD 
chromosomes (%) X z, combined Yules 
Marker and alleles allele method coefficient 
(size, bp) affected normal (P) (a) 
LRT 
(DISLAMB) 
(P) 
D22S275 1 (176) 9 (41) 0 (0) 21 1 
2 (I 74) I (4) 0 (0) (<0.0005) 
3(172) 0(0) 8(15) 
4 (170) 3 (1 3) 14 (26) 
5 (I 68) 3 (I 3) 9 (I 7) 
6 (I 66) 4 (I 8) 9 (I 7) 
7 (164) 2 (9) 13 (24) 
8 (I 62) 0 (0) 0 (0) 
9 (160) 0 (0) 0 (0) 
I 0 (I 58) 0 (0) I (2) 
D22S273 
D22S280 
D22S281 
D22S278 
I (208) 0 (0) I (2) 
2 (206) 0 (0) 2 (4) 
3 (204) 0 (0) I (2) 
4 (202) 2 (9) 2 (4) 
5 (200) 0 (0) I (2) 
6 (198) 18 (81) 8 (15) 
7 (I 96) I (4) 19 (35) 
8 (I 94) I (4) 19 (35) 
9(192) 0(0) 0(0) 
10 (190) 0 (0) 1 (2) 
1 (222) 0 (0) 
2 (220) 0 (0) 
3 (218) 22 (100) 
4(216) 0(0) 
5 (214) 0 (0) 
6(212) 0(0) 
7 (210) 0 (0) 
8 (208) 0 (0) 
I (149) 0 (0) 
2 (I 47) 0 (0) 
3(145) 0(0) 
4 (143) I (4) 
5 (141) I (4) 
6 (I 39) 2 (9) 
7 (137) 0 (0) 
8 (135) 18 (81) 
9(133) 0(0) 
I (243) 0 (0) 
2 (241) I (4) 
3 (239) 6 (27) 
4 (237) 9 (41) 
5 (235) 6 (27) 
6(233) 0(0) 
I (2) 
2(4) 
6(11)  
13(24) 
10(18) 
S(9) 
11 (20) 
6(11) 
3 (6) 
17 (31) 
2(4) 
2(4) 
9 (17) 
6(11) 
2(4) 
11 (2) 
2(4) 
1 (2) 
1 (2) 
9 (17) 
29 (54) 
11 (20) 
3 (6) 
13.3 
1.3 x 10 -4) 
26.3 0.93 27 
(<o.ooo5) (1.2 x lO -7) 
49.33 1 58 
(<0.0005) (1.3 X 10 -14) 
22.5 0.89 22 
(<0.0005) (1.5 x 10 -6) 
1.6 0.25 0 
(0.2) (0.S) 
SFD-associated allele is highlighted in bold. 
tion of haplotypes on normal chromosomes was 
that expected from allele frequencies indicating 
linkage equilibrium between markers. 
A predominant disease haplotype (alleles 
6-3-8) for marker loci D22S273-D22S280- 
D22S281 spanning 3 cM was identified in 11 of 
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15 families (68% of SFD-associated chromo-  
somes). Of the remaining seven SFD-associated 
haplotypes, six differed from the allele order 
6-3-8 at a single locus (families 12, 13, 14, 5d, 5e, 
2b; see Table 2). Family 15 only had one locus 
(D22S280) in common with all of the other  
Sorsby families. Assuming linkage equilibrium, 
the probab i l i ty  of observ ing the hap lo type  
6-3-8 in the  normal  popu la t ion  is 0 .15 
x 0.11 x 0.2 -- 0.003 (0.3%). Extension of this 
haplotype to encompass locus D22S275 identi- 
fied a further preferential haplotype also exclu- 
sive to these SFD chromosomes, comprising the 
significantly associated alleles 1-6-3-8 (locus or- 
der D22S275-D22S273-D22S280-D22S281). This 
haplotype was present in five families (27% SFD 
chromosomes). 
Family 2 (Fig. 2) clearly shows maintainance 
of the ancestral haplotype in branch a of the fam- 
ily, whereas a recombination event in branch b 
places the TIMP3 locus above D22S281 and thus 
in the 3-cM interval between this locus and 
Table 2. Regional Locations and 
Ancestry for Each SFD Family 
Family 
No: Location 
Generations 
traced 
1 Essex 7 
2 Buckinghamshire 9 
3 Greater London 4 
4 Warwickshire 4 
5 Buckinghamshire 7 
6 Cumbria 12 
7 Cumbria 9 
8 Cumbria 7 
9 Hampshire 5 
0 Greater London 3 
1 Merseyside 8 
2 Yorkshire 6 
3 Northamptonshire 3 
4 Eire 7 
5 Merseyside 5 
6 North American 7 
IV 
VI 
D22S275 
D22S273 
D22S280 
D22S281 
D22S278 
I 
-D ~-o  6 6 h • 
6 7 •5  m • • 5•6 5•6 
68 ~3861 ( 78 4/6 4/6 5 7 8 4 4/4 4/4 
27 2 2 515 5/5 
4 4 4 4 3/6 3/6 
mm~ r5 ~- Ui 144  il63 78 77 67 66 58 74 
21 42 88 
64 34 43 
m ~ ~ r~ 6 
87 88 77 77 
46 46 84 84 
22 21 28 28 
46 44 43 33 
42 
53 
m ~ 
3 3 74 46 6 
710 76 6 
38 33 3 
32 14 44 
44 54 54 55 
. . . . .  
m 6 6 d~ 
77 7 10 
43 48 
23 22 42 
44 44 54 
L 35 8 78 47 
82 
54 54 
42 42 
54 54 
FIgure 2 Segregation of marker loci in family 2. Solid symbols signify affected patients. The haplotype segre- 
gating with SFD is boxed. Branch a (1) is seen to carry the probable ancestral haplotype; branch b (11) dem- 
onstrates a recombination event localizing the TIMP3 gene above D22S281; (m) affected individuals not haplo- 
typed. Unknown phase is indicated by a slash between alleles. 
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D22S273. The haplotype present in branch b was 
not observed in any other family. Further evi- 
dence supporting this localization is a single 
crossover event in an unaffected individual of 
family 8 (data not shown). This individual has 
inherited the affected chromosome from her 
mother below locus D22S281 and does not carry 
the Ser181Cys TIMP3 mutation. 
For those families presenting more than one 
disease-associated haplotype, the haplotypes dif- 
fering at just one locus by 2 bp were excluded, as 
it was possible that they may have resulted from 
replication slippage during meiosis and the hap- 
lotype in majority was taken into consideration. 
This enabled the number of SFD-associated hap- 
lotypes to be reduced to 17. For example, in fam- 
ily 5, five haplotypes, a, b, c, d, and e (Table 3), 
can be reduced to two, 1-6-3-8-3 (a, b, c); and 
1-6-3-6-5 (d, e). The common haplotype in fam- 
ily 6 is 6-6-3-8-5 and in family 8 is 5-6-3-8-5. Z2 
values calculated still produced highly significant 
allelic associations for the haplotype 1-6-3-8 and 
6-3-8 (data not shown). The disease-associated 
haplotype was also compared to the North Amer- 
ican family where the Ser181Cys mutation was 
originally described (family 16, Table 3). The 
SFD-associated haplotype 7-7-3-8-4 was exactly 
the same as family 14, which originated from Eire 
(Fig. 3). 
DISCUSSION 
The strongest piece of evidence supporting a 
founder effect in the British SFD study popula- 
tion is the shared Ser181Cys mutation in all af- 
fected individuals. Additionally, there are highly 
significant allelic and haplotype associations be- 
tween SFD and chromosome 22q marker alleles. 
This suggests a founder effect rather than a mu- 
tation hot spot at codon 181. A mutation hot 
spot is not the likely mechanism for single-base 
substitutions in dominant disease, with achon- 
droplasia being the only known exception (Bellus 
et al. 1995). Of the five highly polymorphic 
markers analyzed, four showed significant allelic 
associations with SFD. The most significant asso- 
ciation was between allele 3 at locus D22S280 
(Yules coefficient value - I for linkage disequilib- 
rium) suggesting that this marker locus lies in 
close proximity to the SFD locus. As expected, 
disequilibrium decreases with loci farther centro- 
meric and telomeric than D22S280. However, a 
rise in linkage disequilibrium (Yules coefficient 
value -- 1) for allele 1 at locus D22S275 was seen. 
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This may be explained by the fact that this allele 
is absent in our control population. It cannot be 
attributable to its unique association with dis- 
ease, as there exists a fairly random distribution 
of other D22S275 alleles in the SFD-associated 
haplotypes. In addition, the association of this 
allele with disease was found only to be signifi- 
cant using the conventional X 2 test. 
To study haplotype associations in the 15 
families, two different statistical methods were 
used. The likelihood ratio test has been suggested 
as an improvement on the more conventional Z2 
analysis, by undertaking calculations on the basis 
of multiallelic loci rather than simplifying the 
data to diallelic systems. Both methods gave 
comparable results. The SFD chromosomes 
showed significant association with alleles 1-6- 
3-8 (marker order D22S275-D22S273-D22S280- 
D22S281). Phylogenetic analysis (using Parsi- 
mony version 3.1.1) on all 15 SFD pedigrees ug- 
gested the 1-6-3-8 haplotype to be the founder 
haplotype (data not shown). The CA(n) microsat- 
ellite loci used in haplotype analysis have rela- 
tively high estimated mutation rates of 1/590 
(range 1/726 to 1/450) (Hastabacka et al. 1992), 
which can allow the appearance of new alleles on 
descendants of common ancestral chromosomes. 
This may explain why the founder haplotype is 
observed in only 27% of the SFD families when 
four markers are used. A predominant core hap- 
lotype consisting of alleles 6-3-8 (marker order 
D22S273-D22S280-D22S281) was found to be 
conserved in the vast majority of SFD chromo- 
somes (68%). This kind of conservation i dicates 
identity by decent, which is further supported by 
the fact that these haplotypes are not present on 
nondisease chromosomes. On the basis of allele 
frequencies in the control population and assum- 
ing linkage equilibrium among these marker loci, 
we would have expected a frequency of 0.3% for 
the 6-3-8 haplotype. It is therefore clear that 
there is a striking over-representation of this core 
haplotype (68%) in the SFD population studied. 
Of the seven SFD-associated haplotypes that 
did not have the core 6-3-8 haplotype, one dif- 
fered from the allele order 6-3-8 at a single locus 
(family 14). Here, allele 6 at D22S273 was re- 
placed by allele 7, which was 2 bp larger. Because 
it is possible that this 2-bp difference was attrib- 
utable to replication slippage during meiosis 
rather than recombination, the percentage of 
SFD-associated haplotypes with alleles 6-3-8 
could be increased to 73%. Similarly, of the six 
remaining haplotypes, five differed from this pre- 
 Cold Spring Harbor Laboratory Press on April 11, 2017 - Published by genome.cshlp.orgDownloaded from 
FOUNDER EFFECT IN SORSBY'S FUNDUS DYSTROPHY 
Table 3. SFD-assoclated Haplotypes in 15 British Pedigrees 
Family 
Marker loci and SFD-associated alleles 
no. D22S275 D22S273 D22S280 D2S281 D22S278 
9 
10 
11 
5 
2 
12 
13 
14 
15 
(a) 
(a) 
(b) 
(0 
(a) 
(b) 
(a) 
(b) 
(d) 
(0 
(b) 
iiii~liiiiil~ili~.:...: 
liiiiiiiiiilii~iilii 
5 4 
6 8 
7 7 
5 4 
16 7 7 
5 
4 
5 
5 
5 
4 
4 
4 
5 
4 
5 
2 
4 
4 
4 
The common haplotype is shaded. Family 16 is from North America. 
dominant allele order at single loci. Although 
these could be attributable to real recombination 
events, they could also be explained by muta- 
tions at microsatellite loci; thus, the percentage 
of SFD-associated haplotypes with alleles 6-3-8 
could theoretically be as great as 95%. 
Evidence for the existence of a founder effect 
for the Ser181Cys mutation is thus demonstrated 
with significant linkage disequilibrium over a rel- 
atively large genetic distance. Strong linkage dis- 
equilibrium has been reported with polymor- 
phisms up to 7-10 cM away from a disease- 
associated gene (Blumenfield et al. 1993; Glaser 
et al. 1995). The genetic distance over which link- 
age disequilibrium can be demonstrated is related 
to the number of generations since the origin of 
the mutation. The finding of linkage disequilib- 
rium over a region of 3-4 cM suggests a relatively 
recent origin for the mutation in this study pop- 
ulation. Family 6 has been traced back for 12 gen- 
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Figure 3 Distribution map of the birthplace of the 
earliest founder in each family. The solid circles mark 
the town of birth in the British Isles of the earliest 
member in each family that we could trace by ge- 
nealogy. The numbers refer to family numbers. 
erations to 1711 (-300 years), suggesting the or- 
igin of the mutation to be earlier than this. In 
comparison, 650 kb of DNA in cystic fibrosis has 
been shown as the conserved segment of DNA for 
the founder effect seen in this disease, suggesting 
a much older mutation (Kerem et al. 1989). 
SFD is a rare but well-characterized, blinding 
condition. The actual prevalence in the British 
Isles is unknown. For the purpose of the LRT 
analysis, which requires information on disease 
prevalence, SFD was presumed to have a preva- 
lence rate of 1/100,000. The data base of inher- 
ited eye disease families used constitutes the larg- 
est and best characterized available. We have 
contacted other UK registries and have not found 
any new SFD families. Although the 15 families 
and 76 affected individuals identified o not rep- 
resents the total number, we propose that they 
constitute a significant proportion. The identifi- 
cation of a founder effect was unexpected for a 
number of reasons. The study group represents 
cases from disparate parts of the British Isles, a 
region known to be genetically diverse and het- 
erogeneous with a long history of immigration 
from many parts of the world right up to the 
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present day. For example, a proportion of fami- 
lies with the eye disease retinitis pigmentosa 
from our data base map to six different genetic 
loci. Also, because TIMP3 tissue expression is 
widespread (Wilde et al. 1994), the association 
with nonretinal disease in families 1, 9, and 11 
was thought possibly to imply that each would 
express a different TIMP3 mutation. Interest- 
ingly, TIMP1 is expressed in gingival tissues of 
periodontitis patients (Meikle et al. 1994), and 
the relevance of a similar gum disease associated 
with TIMP3 needs to be investigated further. Sim- 
ilarly, TIMP1 activity has also been detected in 
the optic nerve head (Johnson et al. 1993), a re- 
gion subject o glaucomatous damage. Therefore, 
a role for TIMP3 in a clinically distinct form of 
glaucoma is conceivable. However, the identifi- 
cation of the same mutation in all families sug- 
gests that these associations could now be con- 
sidered either coincidental or related to the con- 
current existence of other predisposing factors in 
those affected pedigrees. 
Further study has also shown that the North 
American family in which the Ser181Cys muta- 
tion was originally identified (Weber et al. 1994b) 
possesses the same disease-associated haplotype 
as the family of Irish descent (family 14) and dis- 
plays the alleles 3-8 for marker loci D22S280 and 
D22S281, respectively, as seen in our SFD fami- 
lies. Interestingly, genealogical evidence indi- 
cates this North American family is of Irish origin 
(Hamilton et al. 1989). It is therefore apparent 
that the Serl81Cys mutation of TIMP3 is the pre- 
dominant SFD mutation within the British Isles; 
therefore, in all cases of suspected SFD, this mu- 
tation should form the basis for genetic screening 
in the United Kingdom. The nonradioactive NsiI 
digest echnique described could therefore be the 
initial test in molecular genetic screening for this 
condition prior to direct sequencing. A simple, 
inexpensive, and reliable screening test such as 
this may be important, as the SFD phenotype can 
sometimes be clinically indistinguishable from 
other hemorrhagic maculopathies, a pathology 
common in the aging populations of the devel- 
oped world. For example, in spite of a number of 
detailed clinical studies on family 6, one individ- 
ual clinically assessed as affected (see Fig. 3 in 
Polkinghorne t al. 1989), on repeated molecular 
genetic testing does not carry the Ser18!Cys 
mutation or the disease-associated hap!otype seg- 
regating in his family. It is therefore possible that 
phenocoples of maculopathies exist, which may 
be important o consider when genetically eval- 
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uat ing  la te -onset  cond i t ions  such  as SFD and 
ARMD.  
SUBJECTS AND MATERIALS 
Pedigrees 
A data base containing clinical information on >4000 fam- 
ilies with different retinal dystrophies was accessed to 
identify SFD families. This data set has been documented 
over the last 25 years and contains families originating 
from throughout the British Isles, including England, Scot- 
land, Wales, and Ireland. A total of 15 different SFD Cau- 
casian families were found that were presumed unrelated 
from genealogical study (Table 2). The earliest founder 
member of each family that we identified was traced using 
a number of different sources available in the United King- 
dom (Jay 1995), including civil registrations of births, mar- 
riages, and deaths, census returns, wills, and church parish 
records. For example, family 6 was traced back 12 genera- 
tions to circa 1700, yet we were unable to connect his 
family to any of the others. The number of generations 
traced in each family is presented in Table 2, and the birth- 
place of the founder in each family is shown in Figure 3. 
Consanguinity was not observed in any of the families. 
From the SFD family set, 166 individuals were enrolled 
into the present study, including 76 affected individuals, 
63 unaffected individuals, and 27 unrelated spouses. The 
inclusion criteria for affected status were that subjects were 
symptomatic by the fourth decade of life with progressive 
loss of visual acuity attributable to choroidal neovascular- 
ization or geographic atrophy. A prolonged choroidal fill- 
ing phase on fluoroscein angiography was the earliest phe- 
notypic marker observed, with later deposition of a con- 
fluent subretinal yellow material at the level of Bruch's 
membrane. These distinct features of the disease distin- 
guish it from other clinical entities such as age-related 
macular degeneration and dominant  drusen phenotypes. 
Detailed clinical data on three of these families (families 2, 
6, and 12) have been described elsewhere (Sorsby and Ma- 
son 1949; Polkinghorne t al. 1989). Additionally, nonret- 
inal disease was seen to segregate significantly with the 
SFD phenotype in three families. Myotonic dystrophy in 
family I segregated over five generations, periodontitis in 
family 11 segregated over six generations, and pigment 
dispersion glaucoma in family 9 segregated over five gen- 
erations (Evans et al. 1995). 
Mutation Detection 
Genomic DNA was extracted from EDTA blood samples 
according to standard procedures (Sambrook et al. 1989). 
For families 2, 6, and 11, DNA was available from members 
of four generations, whereas all others consisted of two 
generation pedigrees with at least two affected and one or 
two unaffected individuals. Initially, direct sequencing of 
exon 5 was performed for at least two affected and one 
unaffected individual per family. The Ser181Cys mutation 
creates a restriction site for the enzyme NsiI. However, the 
radioactive technique described previously to detect the 
NsiI site, amplifying aportion of exon 5, proved inefficient 
in our hands (Weber et al. 1994b). As an alternative, prim- 
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ers amplifying the whole of exon 5 (Weber et al. 1994b) 
from genomic DNA were used. PCR reactions were carried 
out in 20-~1 volumes containing 100 ng of genomic DNA, 
200 nM of each primer, 200 ~m each of dCTP, dATP, dTTP, 
and dGTP in 1 x reaction buffer containing 1 mM MgC12, 
and 0.2 units of Taq polymerase. Thermal cycler settings 
were 94°C for 3 min, followed by 32 cycles of 94°C for 45 
sec, 55°C for 45 sec, and 72°C for 45 sec, followed by a final 
extension at 72°C for 5 min. The resultant fragment was 
digested with NsiI at 37°C and separated on an 8% poly- 
acrylamide nondenatur ing gel. Fragments were then visu- 
alized using ethidium bromide rather than radioactivity. 
This method proved more sensitive and specific and thus 
is a better technique for a rapid screening protocol. 
Detection of Microsatellite Polymorphisms and 
Haplotype Analysis 
Individuals were genotyped by PCR using highly polymor- 
phic CA(n) repeat microsatell ites D22S275, D22S273, 
D22S280, D22S281, and D22S278 (G6n~thon map; Gyapay 
et al. 1994) closely linked to the SFD locus. Primers were 
end-labeled with [7-32p]dATP (3000 gCi) using T 4 polynu- 
cleotide kinase. PCR reactions were carried out in 10-pJ 
volumes as described in the mutation detection method 
above, except hat 1.5 mM MgC12 was used and the anneal- 
ing temperature varied from 55°C to 60°C. The amplified 
products were resolved on 6% polyacrylamide sequencing 
gels containing 6 M urea. Genotypes were ascertained after 
autoradiographic exposure. 
Parental haplotypes for the microsatellite markers 
were examined to ensure correct assignment of disease 
haplotype, and in a few circumstances where DNA was 
unavailable from a parent, the haplotype data were in- 
ferred with the aid of siblings and other family members. 
Statistical Analysis 
One affected individual from each of the 15 families was 
selected for analysis; however, in families in which recom- 
bination events had occurred, two or more affected hap- 
lotypes were taken into consideration. Twenty-seven un- 
affected spouses contributed as controls for the assessment 
of allele frequencies, a  these differed to the published fre- 
quencies in the CEPH families and for haplotype analysis. 
To test the null hypothesis of no association of marker 
alleles with disease (no linkage disequilibrium), the fre- 
quency distribution of alleles on disease- and nondisease- 
bearing chromosomes were analyzed across all families us- 
ing two different statistical methods. 
~2 Analysis Using a Combined Allele Plethod 
For each marker, this involved designation of the allele 
that was over-represented among SFD chromosomes as 
one allele, with the pooling of the remaining alleles to 
form a second allele. A standard Z 2 test of independence 
was then calculated using a 2 x 2 contingency table with 
Yates correction at 1 degree of freedom (df). The degree of 
association was measured by Yules coefficient (5) as dem- 
onstrated in Aksentijevich and co-workers (1993). 
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LRT /or Linkage Disequilibrium 
This likelihood-based test was undertaken using the pro- 
gram DISLAMB (Terwilliger 1995), which accounts for 
markers with multiple alleles and calculates a simple like- 
lihood ratio of association with appropriate P values of 
significance. 
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